Immunomedics Company Profile (NASDAQ:IMMU)

Analyst Ratings

Consensus Ratings for Immunomedics (NASDAQ:IMMU) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $5.00 (88.68% upside)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016Wells Fargo & Co.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Jefferies GroupReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2015Oppenheimer Holdings Inc.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2014Panmure GordonReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/27/2014R. F. LaffertyDowngradeBuy -> Neutral$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Immunomedics (NASDAQ:IMMU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/4/2016        
5/4/2016Q3($0.13)($0.15)$2.13 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2016Q216($0.14)($0.15)$1.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q116($0.14)($0.16)$1.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015($0.13)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2015Q215($0.13)($0.12)$1.38 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014($0.12)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/25/2014Q414($0.12)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014($0.11)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immunomedics (NASDAQ:IMMU)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Immunomedics (NASDAQ:IMMU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Immunomedics (NASDAQ:IMMU)
DateHeadline
07/30/16 07:32 AMINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Immunomedics, Inc. of a Class Action Lawsuit and ... - Business Wire (press release)
07/29/16 10:11 AMIMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Immunomedics Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - IRVINE, CA / ACCESSWIRE / July 29, 2016 / Khang & Khang LLP (the "Firm") announces that a class action lawsuit was filed against Immunomedics Inc. ("Immunomedics" or the "Company") ...
07/29/16 08:35 AMINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Immunomedics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 - [Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:
07/28/16 02:45 PMBrower Piven Alerts Shareholders of Upcoming Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Immunomedics, Inc. to Contact the Firm - IMMU - [GlobeNewswire] - STEVENSON, Md., July 28, 2016-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ...
07/28/16 07:37 AMIntraday Active Biotech Stocks News: Immunomedics Inc. (NASDAQ:IMMU), Keryx Biopharmaceuticals Inc. (NASDAQ ... - The Voice Registrar
07/27/16 07:26 AMImmunomedics, Inc. (IMMU) Updated Price Targets - FTSE News
07/27/16 07:26 AMRecent Analysts Rating Overview: Abbott Laboratories (NYSE:ABT ... - Street Updates
07/27/16 07:26 AMNoteworthy Buzzers: Endo International plc (NASDAQ:ENDP) , Immunomedics, Inc. (NASDAQ:IMMU) - Street Updates
07/26/16 10:53 AMIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Immunomedics Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - LOS ANGELES, CA / ACCESSWIRE / July 26, 2016 / Lundin Law PC (the "Firm") announces that a class action lawsuit was filed against Immunomedics Inc. ("Immunomedics" or the "Company") ...
07/26/16 09:24 AMDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of a Class Action against Immunomedics Inc. (IMMU) and Lead Platintiff Deadline: August 8, 2016 - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 26, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against Immunomedics, Inc. ("Immunomedics" or the "Company") (NASDAQ-GM: ...
07/25/16 04:41 PMImmunomedics Inc. (NASDAQ:IMMU) at $2.68: How much higher it can go - Review Fortune
07/25/16 09:24 AMSHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Immunomedics, Inc. and a Lead Plaintiff Deadline of August 8, 2016 - IMMU - [Business Wire] - The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc.
07/25/16 09:11 AMTake a look at Analyst Tips: Baxter International Inc. (NYSE:BAX) , Immunomedics, Inc. (NASDAQ:IMMU) - Street Updates
07/25/16 09:11 AMHC Stocks Assessment: Adeptus Health Inc (NYSE:ADPT) Immunomedics, Inc. (NASDAQ:IMMU) - share market updates (press release)
07/25/16 04:45 AMINVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Immunomedics Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - IRVINE, CA / ACCESSWIRE / July 25, 2016 / Khang & Khang LLP (the "Firm") announces that a class action lawsuit was filed against Immunomedics Inc. ("Immunomedics" or the "Company") ...
07/24/16 08:59 AMPomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunomedics, Inc. of Class Action Lawsuit and Upcoming Deadline – IMMU
07/24/16 08:00 AMSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunomedics, Inc. of Class Action Lawsuit and Upcoming Deadline – IMMU - [GlobeNewswire] - NEW YORK, July 24, 2016-- Pomerantz LLP announces that a class action lawsuit has been filed against Immunomedics, Inc. and certain of its officers. The class action, filed in United States District Court, ...
07/22/16 09:17 PMIMMUNOMEDICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Immunomedics Inc. - [Business Wire] - Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 8, 2016 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics Inc.
07/21/16 04:48 PMThree Movers to Watch for: Pebblebrook Hotel Trust (PEB), Immunomedics Inc. (IMMU), Flowserve Corp. (FLS) - iStreetWire
07/21/16 04:48 PMStocks inside Analysts Limelight: Infinity Pharmaceuticals, Inc ... - Street Updates
07/21/16 11:07 AMIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Immunomedics Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - LOS ANGELES, CA / ACCESSWIRE / July 21, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company") (NASDAQ: IMMU) ...
07/21/16 10:40 AMImmunomedics, Inc. (IMMU) Current Analyst Ratings - Fiscal Standard
07/21/16 10:40 AMTrading the Biotech News: Cerus Corporation (NASDAQ:CERS), Immunomedics Inc. (NASDAQ:IMMU) - The Voice Registrar
07/21/16 10:40 AMCould Immunomedics, Inc. See a Reversal After This Very Strong Session? - Consumer Eagle
07/21/16 10:40 AMPerformance to see: Immunomedics Inc. (NASDAQ:IMMU) - News Oracle
07/21/16 10:40 AMImmunomedics Inc. (IMMU) Jumps 11.01% on July 20 - Equities.com
07/20/16 02:37 PMINVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Immunomedics, …
07/20/16 09:23 AMINVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Immunomedics, Inc. and a Lead Plaintiff Deadline of August 8, 2016 - IMMU - [PR Newswire] - NEW YORK, July 20, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased ...
07/19/16 04:43 PMTrader's Watch List: Immunomedics, Inc. (NASDAQ:IMMU), Bank of America Corp(NYSE:BAC) - NYSE Journal (press release)
07/19/16 10:43 AMGlobal Cancer Immunotherapy Market Analysis and Forecast by Segment, Product Segment and Company in 2016 Report
07/19/16 09:15 AMDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Immunomedics Inc. (IMMU) & Lead Platintiff Deadline: August 8, 2016 - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against of Immunomedics, Inc. ("Immunomedics" or the "Company") (NASDAQ ...
07/18/16 05:33 PMEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Immunomedics, Inc. - IMMU - [GlobeNewswire] - NEW YORK, July 18, 2016-- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Immunomedics, Inc. securities from April 20, 2016 ...
07/18/16 04:48 PMCancer immunotherapy drugs market to account $80 billion in 2020 according to new research report
07/18/16 09:50 AMShares Moving Down on the Week: Immunomedics Inc. (NASDAQ:IMMU) - Engelwood Daily
07/18/16 09:50 AMImmunomedics Inc. (NASDAQ:IMMU) Increased 3.64%: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Comcast ... - KC Register
07/18/16 09:50 AMImmunomedics, Inc. (IMMU) Broker Price Targets For The Coming Week - Fiscal Standard
07/16/16 04:21 PMFrance Reveals Details on Attacker in Nice
07/16/16 07:59 AMShares Experiencing a Downtrend: Immunomedics Inc. (NASDAQ:IMMU) - TGP
07/16/16 07:59 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Immunomedics, Inc. of Commencement of a ... - Business Wire (press release)
07/15/16 12:17 PMSHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Immunomedics Inc. and Encourages Investors with Losses to Contact the Firm - [Business Wire] - Goldberg Law PC announces that a class action lawsuit has been filed against Immunomedics Inc. . Investors who purchased or otherwise acquired shares between April 20, 2016 and June 2, 2016 , are encouraged to contact the firm in advance of the August 8, 2016 lead plaintiff motion deadline.
07/15/16 08:15 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Immunomedics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 - [Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:
07/15/16 08:13 AMImmunomedics Inc. (IMMU) Drops 5.22% on July 13 - Equities.com
07/14/16 12:10 PMIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Immunomedics Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - IRVINE, CA / ACCESSWIRE / July 14, 2016 / Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company") ...
07/14/16 09:20 AMSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of a Class Action against Immunomedics Inc. (IMMU) and Lead Platintiff Deadline August 8, 2016 - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 14, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors of a class action against Immunomedics, Inc. ("Immunomedics" or the "Company") (NASDAQ-GM: ...
07/14/16 08:07 AMAnalyst's Stocks Ratings Trend: Bristol-Myers Squibb Company (NYSE:BMY) , Immunomedics, Inc. (NASDAQ:IMMU) - Street Updates
07/14/16 08:07 AMOption Market: Immunomedics Inc Risk Hits An Extreme High - CML News
07/13/16 07:30 AMAnalyst Recommended Stock: Immunomedics Inc. (NASDAQ:IMMU) - News Oracle
07/13/16 07:30 AMImmunomedics Inc. (IMMU) Drops 7.26% on July 11 - Equities.com
07/12/16 08:59 AMHealthcare Losers: Sarepta Therapeutics (NASDAQ:SRPT), Stellar Biotechnologies (NASDAQ:SBOT), Immunomedics ... - KC Register
07/12/16 08:59 AMWhich way Immunomedics Inc. (NASDAQ:IMMU) insiders are heading - Review Fortune

Social

About Immunomedics

Immunomedics logoImmunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company's technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It has other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in clinical and pre-clinical development-stages.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IMMU
  • CUSIP: 45290710
Key Metrics:
  • Previous Close: $2.61
  • 50 Day Moving Average: $2.49
  • 200 Day Moving Average: $2.76
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $251.23M
  • Beta: 1.37
  • Current Year EPS Consensus Estimate: $-0.56 EPS
  • Next Year EPS Consensus Estimate: $-0.47 EPS
Additional Links:
Immunomedics (NASDAQ:IMMU) Chart for Saturday, July, 30, 2016